In contrast, a prospective observational study by Dixon et al. involving a sample population of 367 patients with RA-ILD demonstrated that the mortality rate was not increased after treatment with anti-TNF agents compared with traditional immunomodulatory drugs (Table 1) [74]. The gene discussed is TNF; the disease is rheumatoid arthritis.